CGS 21680 hydrochloride

Research use only, not for human use.

CGS 21680 is a specific adenosine A2A subtype receptor agonist with Ki of 27 nM.

CGS 21680 is a specific adenosine A2A subtype receptor agonist with Ki of 27 nM; significantly upregulates CD39 and CD73 expression, accelerates the ATP hydrolysis and adenosine generation; reduces the number of infiltrated granulocytes into the ischemic tissue in rat model of transient cerebral ischemia.Hypertension Discontinued.

CGS21680 significantly upregulates CD39 and CD73 expression. CGS21680 accelerates the adenosine triphosphate (ATP) hydrolysis and adenosine generation. CGS21680 (10 nM) alone shows only small survival activity, but the activity is significantly enhanced by the addition of a phosphodiesterase inhibitor, IBMX. The survival activity of CGS21680 on cultured motoneurons is exerted by mixed effects of the adenylate cyclase-cAMP-PKA pathway and the transactivation of neurotrophin receptors.

CGS21680 (1 mg/kg/i.p.) intervention promotes the development of EAN. CGS21680 exacerbates experimental autoimmune neuritis in Lewis rats induced with bovine peripheral myelin. The exacerbation is accompanied with reduced CD4+ Foxp3+ T cells, increased CD4+ CXCR5+ T cells, B cells, dendritic cells and antigen-specific autoantibodies, which is possibly due to the inhibition of IL-2 induced by CGS21680. CGS21680 (0.1 mg/kg, i.p.) transiently increases heart frequency but does not modify blood pressure of rat, and does not modify either heart frequency or blood pressure at 0.01 mg/kg. Following transient MCAo, CGS21680 at both doses protects from neurological deficit from the first day up to 7 days thereafter. At this time, it has reduced microgliosis, astrogliosis and improved myelin organization in the striatum and cytoarchitecture of the ischemic cortex and striatum. Two days after transient MCAo, CGS21680 has reduced the number of infiltrated granulocytes into the ischemic tissue.

CGS-21680 Hydrochloride | CGS21680 Hydrochloride

GPCR/G Protein

Adenosine Receptor

A2

Cardiovascular Disease

Hypertension

124431-80-7

535.9806

C23H30ClN7O6

>98% (HPLC)

DMSO: ≥ 20 mg/mL

CCNC(=O)C1C(C(C(O1)N2C=NC3=C(N=C(N=C32)NCCC4=CC=C(C=C4)CCC(=O)O)N)O)O.Cl

3-(4-(2-((6-amino-9-((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl)amino)ethyl)phenyl)propanoic acid hydrochloride

(-20℃)

With Ice Pack

≥ 2 years